PT2982982T - Metedo para rastreio de compostos utilizando uma membrana stim1 - Google Patents

Metedo para rastreio de compostos utilizando uma membrana stim1 Download PDF

Info

Publication number
PT2982982T
PT2982982T PT142902329T PT14290232T PT2982982T PT 2982982 T PT2982982 T PT 2982982T PT 142902329 T PT142902329 T PT 142902329T PT 14290232 T PT14290232 T PT 14290232T PT 2982982 T PT2982982 T PT 2982982T
Authority
PT
Portugal
Prior art keywords
leu
cells
ser
glu
stim1
Prior art date
Application number
PT142902329T
Other languages
English (en)
Portuguese (pt)
Inventor
Renaudineau Yves
Mignen Olivier
Burgos Miguel
Olivier Pers Jacques
Fali Tinhinane
Original Assignee
Univ De Bretagne Occidentale U B O
Inst Nat Sante Rech Med
Centre Hospitalier Rãgional Et Univ De Brest
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ De Bretagne Occidentale U B O, Inst Nat Sante Rech Med, Centre Hospitalier Rãgional Et Univ De Brest filed Critical Univ De Bretagne Occidentale U B O
Publication of PT2982982T publication Critical patent/PT2982982T/pt

Links

Classifications

    • G01N33/57505—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT142902329T 2014-08-06 2014-08-06 Metedo para rastreio de compostos utilizando uma membrana stim1 PT2982982T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14290232.9A EP2982982B1 (en) 2014-08-06 2014-08-06 Method of screening of compounds using membrane STIM1

Publications (1)

Publication Number Publication Date
PT2982982T true PT2982982T (pt) 2018-01-03

Family

ID=51398585

Family Applications (1)

Application Number Title Priority Date Filing Date
PT142902329T PT2982982T (pt) 2014-08-06 2014-08-06 Metedo para rastreio de compostos utilizando uma membrana stim1

Country Status (11)

Country Link
US (2) US20170219588A1 (enExample)
EP (2) EP2982982B1 (enExample)
JP (2) JP6754751B2 (enExample)
CN (2) CN110051836B (enExample)
CA (1) CA2952159C (enExample)
DK (1) DK2982982T3 (enExample)
ES (1) ES2654674T3 (enExample)
NO (1) NO2982982T3 (enExample)
PL (1) PL2982982T3 (enExample)
PT (1) PT2982982T (enExample)
WO (1) WO2016020274A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3714943A1 (en) 2019-03-25 2020-09-30 Université De Bretagne Occidentale - UBO Monoclonal antibody against stim1
EP3715848A1 (en) * 2019-03-25 2020-09-30 Université de Bretagne Occidentale (U.B.O.) Substance interacting with c terminal fragment of the stim1 fraction localized to the plasma membrane of the cells, for its use in the treatment of cancers, and in screening and diagnostic methods
EP3714942A1 (en) * 2019-03-25 2020-09-30 Université De Bretagne Occidentale - UBO Monoclonal antibody against stim1
US20240083990A1 (en) * 2021-01-26 2024-03-14 Universite Brest Bretagne Occidentale Novel stim1 splicing variants and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2341484T3 (es) * 2005-05-20 2010-06-21 Genentech, Inc. Pretratamiento de una muestra biologica de un sujeto que sufre una enfermedad autoinmune.
WO2008148108A1 (en) * 2007-05-24 2008-12-04 Calcimedica, Inc. Calcium channel proteins and uses thereof
US20160169868A9 (en) * 2007-05-24 2016-06-16 Calcimedica, Inc. Calcium channel proteins and uses thereof
EP2472262A3 (en) * 2007-07-10 2012-10-17 Immune Disease Institute, Inc. Stromal interacting molecule knockout mouse and uses thereof
WO2009021338A1 (en) * 2007-08-15 2009-02-19 UNIVERSITé DE SHERBROOKE Alternative splicing gene variants in cancer detection
AU2008299220B2 (en) * 2007-09-10 2011-07-21 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2103311A1 (en) * 2008-03-20 2009-09-23 CSL Behring GmbH The calcium sensor STIM1 is essential for pathological thrombus formation
WO2010099401A1 (en) * 2009-02-26 2010-09-02 The Board Of Trustees Of The Leland Stanford Junior University Calcium signaling modulators involving stim and orai proteins
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US20160194393A1 (en) * 2011-08-10 2016-07-07 Biommune Technologies Inc. Methods and compositions for modulating voltage-gated calcium channel function
CN102433383B (zh) * 2011-12-19 2015-07-08 上海吉凯基因化学技术有限公司 人stim1基因的用途及其相关药物

Also Published As

Publication number Publication date
NO2982982T3 (enExample) 2018-03-03
JP2019214576A (ja) 2019-12-19
JP6861246B2 (ja) 2021-04-21
CA2952159A1 (en) 2016-02-11
PL2982982T3 (pl) 2018-03-30
EP3177929A1 (en) 2017-06-14
US20170219588A1 (en) 2017-08-03
JP6754751B2 (ja) 2020-09-16
JP2017531164A (ja) 2017-10-19
EP2982982B1 (en) 2017-10-04
CN110051836A (zh) 2019-07-26
ES2654674T3 (es) 2018-02-14
CN106716130B (zh) 2019-03-29
EP2982982A1 (en) 2016-02-10
US20190154690A1 (en) 2019-05-23
CA2952159C (en) 2022-08-30
DK2982982T3 (en) 2018-01-08
WO2016020274A1 (en) 2016-02-11
CN110051836B (zh) 2023-05-26
EP3177929B1 (en) 2018-05-09
CN106716130A (zh) 2017-05-24

Similar Documents

Publication Publication Date Title
Krock et al. Fibromyalgia patients with elevated levels of anti–satellite glia cell immunoglobulin G antibodies present with more severe symptoms
Zhong et al. Temporal profiling of the secretome during adipogenesis in humans
Van Berlo et al. A-type lamins are essential for TGF-β1 induced PP2A to dephosphorylate transcription factors
Dvořánková et al. Human galectins induce conversion of dermal fibroblasts into myofibroblasts and production of extracellular matrix: potential application in tissue engineering and wound repair
Wang et al. FGFR3/fibroblast growth factor receptor 3 inhibits autophagy through decreasing the ATG12–ATG5 conjugate, leading to the delay of cartilage development in achondroplasia
Sanchez-Ruderisch et al. Galectin-1 sensitizes carcinoma cells to anoikis via the fibronectin receptor α5β1-integrin
Bai et al. Role of acid sphingomyelinase bioactivity in human CD4+ T-cell activation and immune responses
dela Paz et al. Heparan sulfates mediate the interaction between platelet endothelial cell adhesion molecule-1 (PECAM-1) and the Gαq/11 subunits of heterotrimeric G proteins
Bck et al. Insulin and IGF1 receptors in human cardiac microvascular endothelial cells: metabolic, mitogenic and anti-inflammatory effects
Peterson et al. Frizzled-5: a high affinity receptor for secreted frizzled-related protein-2 activation of nuclear factor of activated T-cells c3 signaling to promote angiogenesis
Nakamura et al. Loss-of-function and gain-of-function mutations of calcium-sensing receptor: functional analysis and the effect of allosteric modulators NPS R-568 and NPS 2143
Sun et al. Romo1 is involved in the immune response of glioblastoma by regulating the function of macrophages
PT2982982T (pt) Metedo para rastreio de compostos utilizando uma membrana stim1
Alenmyr et al. TRPV1 and TRPA1 stimulation induces MUC5B secretion in the human nasal airway in vivo
Lu et al. HGAL, a lymphoma prognostic biomarker, interacts with the cytoskeleton and mediates the effects of IL-6 on cell migration
Elshamly et al. Galectins‐1 and‐3 in human intervertebral disc degeneration: non‐uniform distribution profiles and activation of disease markers involving NF‐κB by galectin‐1
Cai et al. BRD1-mediated acetylation promotes integrin αV gene expression via interaction with sulfatide
Agbor et al. The ERM protein, ezrin, regulates neutrophil transmigration by modulating the apical localization of MRP2 in response to the SipA effector protein during Salmonella Typhimurium infection
Bachmann et al. Actin‐binding protein filamin A is displayed on the surface of human neuroblastoma cells
Pye et al. Chemokine unresponsiveness of chronic lymphocytic leukemia cells results from impaired endosomal recycling of Rap1 and is associated with a distinctive type of immunological anergy
Lakomá et al. Characterization of human dermal fibroblasts in Fabry disease
Liu et al. The interplay between oxytocin receptor and YAP in regulating gastric cancer progression
Moriggi et al. Characterization of proteome changes in aged and collagen VI-deficient human pericyte cultures
Zhang et al. Identification and characterization of a carbohydrate recognition domain-like region in Entamoeba histolytica Gal/GalNAc lectin intermediate subunit
Leunissen et al. Urinary β-galactosidase stimulates Ca2+ transport by stabilizing TRPV5 at the plasma membrane